Chemicals

Amyris Plans Acquisition of Sweet Protein Developer Oobli

The biomanufacturing company intends to combine its strain engineering and commercial scale with Oobli’s fermentation-derived sweet protein platform.

Soren LindqvistNovember 16, 20265 min read0 views

A stainless-steel bioreactor and abstract berry forms are linked by luminous protein strands in a clean editorial illustration.

Amyris Inc. has announced plans to acquire Oobli Inc., a Davis, California-based company that Amyris describes as the leading innovator in fermentation-derived sweet proteins. Amyris, based in Emeryville, California, is a vertically integrated biomanufacturing company. Oobli’s ingredients are intended to help food and beverage brands reduce sugar without sacrificing taste. The acquisition is expected to close in the coming weeks.

The companies said the transaction combines Amyris’s scientific capabilities and manufacturing depth with Oobli’s expertise in protein fermentation. It follows Amyris’s expansion earlier this year of manufacturing capacity at its advanced fermentation facility in Barra Bonita, Brazil. Amyris frames the acquisition as a commercial and technology expansion that should accelerate its position in protein- and peptide-based solutions across end markets.

Combined platform and product portfolio

Oobli’s commercial portfolio of sweet proteins will be the first to benefit from the combined platform. Oobli has spent the past decade refining a fermentation process for producing sweet proteins that occur naturally in rare fruits and berries near the equator. According to Oobli, these proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein, delivering sweetness without gut disruption or blood sugar spikes.

Oobli’s portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit sweet proteins, known scientifically as brazzein, monellin and thaumatin, respectively. The ingredients have FDA GRAS status as an ingredient and are FEMA GRAS-affirmed for use as a natural flavor. Oobli describes them as the first of their kind in the sugar-reduction category. The company sees potential demand across sports and nutrition, dairy, beverages, chocolate, bakery and confectionery as consumers become more aware of metabolic health and sugar reduction.

Leadership views

Amyris CEO Kathy Fortmann said Oobli’s commercial and technology platform is a strong complement to Amyris. She said Oobli is positioned to change how sweetness reaches the market, and that Amyris can add commercial scale and resources to accelerate that effort. Combining Oobli’s protein expertise with Amyris’s strain engineering, manufacturing scale and commercial capabilities could broaden the combined company’s work in food and beverage, personal care, flavor and fragrance, agriculture and other markets, Fortmann said.

Oobli CEO Ali Wing said the company has long believed there is a better way to deliver the sweet taste consumers want without trade-offs to health and the environment. She said joining Amyris would provide the scale and resources to pursue Oobli’s ambition of making sweet proteins a global standard in sweetness solutions. Fortmann added that biomanufactured solutions succeed when they align with consumer demand and market needs, and that Oobli’s platform supports sweet taste, sugar reduction and clean-label goals at the same time.

Amyris said existing customer commitments and brand partnerships will continue without interruption as Oobli’s sweet protein portfolio expands within the company.